| Literature DB >> 22093584 |
Muhamed Baljevic1, Jae H Park, Eytan Stein, Dan Douer, Jessica K Altman, Martin S Tallman.
Abstract
The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.Entities:
Mesh：
Year: 2011 PMID： 22093584 PMCID： PMC4021483 DOI： 10.1016/j.hoc.2011.10.002
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN： 0889-8588 Impact factor: 3.722